* Celgene receives constructive CHMP opinion to broaden REVLIMID (lenalidomide) indication as monotherapy for the upkeep therapy of sufferers with newly recognized a number of myeloma (mm) after autologous stem cell transplantation

* Celgene Corp- European fee, which typically follows advice of chmp, is anticipated to make its ultimate choice in roughly two months

* New indication expands availability of revlimid throughout illness continuum of a number of myeloma Source textual content for Eikon: Further firm protection:





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here